Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 301–400 of 1,000
Verma, I. M. (2013) · Science · doi:10.1126/science.1242551 · Cited by 60
Lentiviral Vector Integration Profiles Differ in Rodent Postmitotic Tissues
Bartholomae, C. C., Arens, A., Balaggan, K. S., Yáñez‐Muñoz, R. J., Montini, E., Howe, S. J., Paruzynski, A., Korn, B., Appelt, J. U., MacNeil, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.19 · Cited by 60
Wakabayashi, T., Shimada, Y., Akiyama, K., Higuchi, T., Fukuda, T., Kobayashi, H., Eto, Y., Ida, H., & Ohashi, T. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.158 · Cited by 57
Pluripotent stem cell applications for regenerative medicine
Angelos, M. G., & Kaufman, D. S. (2015) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000244 · Cited by 58
“Based on previous studies demonstrating the correction of β-thalassemia in hematopoietic stem cells by lentiviralmediated TALEN delivery [65], Xie, et al.”
Coquerelle, S., Ghardallou, M. E., Ali, S. R., Taupin, P., Touzot, F., Boquet, L., Blanche, S., Benaouadi, S., Brice, T., Tuchmann‐Durand, C., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.178 · Cited by 54
Schott, J. W., León‐Rico, D., Ferreira, C. B., Buckland, K. F., Santilli, G., Armant, M. A., Schambach, A., Cavazza, A., & Thrasher, A. J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.015 · Cited by 54
Gene therapy for monogenic disorders of the bone marrow
Ghosh, S., Thrasher, A. J., & Gaspar, H. B. (2015) · British Journal of Haematology · doi:10.1111/bjh.13520 · Cited by 56
Gellhaus, B., Böker, K. O., Schilling, A. F., & Saul, D. (2023) · Cells · doi:10.3390/cells12242787 · Cited by 58
“For an observational time of 8 weeks, a stable knockdown was observed, indicating its potential for gene silencing [132] (Figure 5).”
BackgroundUbiquitous Chromatin-opening Elements (UCOEs): Applications in biomanufacturing and gene therapy
Neville, J. J., Orlando, J., Mann, K., McCloskey, B., & Antoniou, M. N. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.05.004 · Cited by 60
“A number of studies have reported examples of vector-mediated aberrant splicing, a potential source of vector toxicity (Almarza et al., 2011; Cavazzana-Calvo et al., 2010; Moiani et al., 2012; Montini et al., 2009).”
BackgroundAdenovirus vectors in hematopoietic stem cell genome editing
Li, C., & Lieber, A. (2019) · FEBS Letters · doi:10.1002/1873-3468.13668 · Cited by 58
Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies
Payen, E., & Leboulch, P. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.276.3807841 · Cited by 59
Self-citationTargeted plasmid integration into the human genome by an engineered zinc-finger recombinase
Gersbach, C. A., Gaj, T., Gordley, R. M., Mercer, A. C., & Barbas, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr421 · Cited by 58
Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
Ferrari, S., Vavassori, V., Canarutto, D., Jacob, A., Castiello, M. C., Omer, A., & Genovese, P. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618378 · Cited by 57
“However, some genotoxicity events might still occur upon LV integration, such as the vectormediated disruption of relevant genomic elements or tumor suppressor genes and/or the generation of aberrant splicing variants of endogenous genes fused to the transgene cassette (Cavazzana-Calvo et al., 2010).”
BackgroundModulating microRNAs in cancer: Next-generation therapies
Arghiani, N., & Shah, K. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0294 · Cited by 66
Gene therapy for hemoglobinopathies: progress and challenges
Dong, A., Rivella, S., & Breda, L. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.011 · Cited by 60
Khandros, E., & Kwiatkowski, J. L. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.003 · Cited by 61
“Beta globin replacement The first human gene therapy trial for beta thalassemia was published in 2010.(46) Using a lentiviral vector expressing b globin with a T87Q mutation that mimics the”
BackgroundSplicing modulation therapy in the treatment of genetic diseases
Aartsma-Rus, A. M., Arechavala‐Gomeza, V., & Khoo, B. C. E. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s71506 · Cited by 60
Corrigan‐Curay, J., Cohen‐Haguenauer, O., O’Reilly, M., Ross, S. R., Fan, H., Rosenberg, N. E., Somia, N. V., King, N. M. P., Friedmann, T., Dunbar, C. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.93 · Cited by 57
Self-citationTargeted approaches to induce immune tolerance for Pompe disease therapy
Doerfler, P. A., Nayak, S., Corti, M., Morel, L. M., Herzog, R. W., & Byrne, B. J. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.53 · Cited by 55
Poletti, V., Charrier, S., Corre, G., Gjata, B., Vignaud, A., Zhang, F., Rothe, M., Schambach, A., Gaspar, H. B., Thrasher, A. J., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.002 · Cited by 54
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 53
“…require long-term monitoring to determine the level of safety of using viral vectors in CAR T cells, however, no reported adverse events to viral vectors have been documented so far (Cavazzana-Calvo et al., 2010; Aiuti et al., 2013; Biffi et al., 2013; McGarrity et al., 2013; Sessa et al., 2016).”
BackgroundEvolution of hemoglobin loci and their regulatory elements
Philipsen, S., & Hardison, R. C. (2018) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2017.08.001 · Cited by 51
Genetic correction using engineered nucleases for gene therapy applications
Li, H. L., Nakano, T., & Hotta, A. (2013) · Development Growth & Differentiation · doi:10.1111/dgd.12107 · Cited by 57
Genome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 51
Sherrill-Mix, S. A., Ocwieja, K. E., & Bushman, F. D. (2015) · Retrovirology · doi:10.1186/s12977-015-0205-1 · Cited by 54
“However, another common mechanism involves formation of chimeric messages involving both cellular and viral/vector sequences [57, 58].”
BackgroundSelf-citationHematopoietic Stem Cell Transplantation for Thalassemia
Gaziev, J., & Lucarelli, G. (2011) · Current Stem Cell Research & Therapy · doi:10.2174/157488811795495413 · Cited by 52
Stem cell-based anti-HIV gene therapy
Kitchen, S. G., Shimizu, S., & An, D. S. (2011) · Virology · doi:10.1016/j.virol.2010.12.039 · Cited by 56
“However, a recent thalassaemia stem cell based gene therapy using a lentiviral vector provides us a cautionary tale (Cavazzana-Calvo et al., 2010).”
BackgroundViral vectors for gene therapy and gene modification approaches
Merten, O., & Gaillet, B. (2015) · Biochemical Engineering Journal · doi:10.1016/j.bej.2015.09.005 · Cited by 57
Antoniani, C., Romano, O., & Miccio, A. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0192 · Cited by 57
Greene, M. R., Lockey, T., Mehta, P. K., Kim, Y.-S., Eldridge, P. W., Gray, J. T., & Sorrentino, B. P. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.150 · Cited by 47
“Lentiviral vectors can potentially cause clonal imbalance in human subjects (Cavazzana-Calvo et al., 2010) and leukemia in animal models (Montini et al., 2009), suggesting the need to limit the vector copy number.”
BackgroundResultEvolution of Gene Therapy, Historical Perspective
Malech, H. L., Garabedian, E., & Hsieh, M. M. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.05.001 · Cited by 54
Chuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 58
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · PubMed · doi:10.1182/asheducation-2012.1.375 · Cited by 52
Therapy Development by Genome Editing of Hematopoietic Stem Cells
Koniali, L., Lederer, C. W., & Kleanthous, M. (2021) · Cells · doi:10.3390/cells10061492 · Cited by 54
Gene Therapy for Hemoglobinopathies
Leonard, A. K., Tisdale, J. F., & Bonner, M. A. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.008 · Cited by 55
Host Factors in Retroviral Integration and the Selection of Integration Target Sites
Craigie, R., & Bushman, F. D. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0026-2014 · Cited by 45
Self-citationOptimizing Retroviral Gene Expression for Effective Therapies
Antoniou, M. N., Skipper, K. A., & Anakök, Ö. F. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.062 · Cited by 55
Zimmermann, K., Scheibe, O., Kocourek, A., Muelich, J., Jurkiewicz, E., & Pfeifer, A. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-55 · Cited by 48
Retroviral Vectors: Post Entry Events and Genomic Alterations
Nowrouzi, A., Glimm, H., Kalle, C. V., & Schmidt, M. (2011) · Viruses · doi:10.3390/v3050429 · Cited by 51
“Such insertional alterations in the regulation of the cellular genome by LV-vectors have recently been reported in the gene therapy trial for human β-thalassaemia [118].”
BackgroundInfluentialClinical translation of gene medicine
Wang, F., Qin, Z., Lu, H., He, S., Luo, J. C., Jin, C., & Song, X. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3108 · Cited by 48
De Ravin, S. S., Liu, S., Sweeney, C. L., Brault, J., Whiting-Theobald, N., Ma, M., Liu, T., Choi, U., Lee, J., O’Brien, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31344-x · Cited by 51
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
“Moreover, recombination at the post-transcriptional level, for example, between splicing sites of the viral RNA and the host RNAs, is another treatment to consider [19], even if it can sometimes be beneficial for the treatment [20].”
BackgroundGene therapy for primary immunodeficiencies: Looking ahead, toward gene correction
Pessach, I. M., & Notarangelo, L. D. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.02.027 · Cited by 54
Barde, I., Laurenti, E., Verp, S., Wiznerowicz, M., Offner, S., Viornery, A., Galy, A. H. M., Trumpp, A., & Trono, D. (2011) · Gene Therapy · doi:10.1038/gt.2011.65 · Cited by 50
Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes
Rouanet, M., Lebrin, M., Gross, F., Bournet, B., Cordelier, P., & Buscail, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061231 · Cited by 50
“This method applies very well to blood stem cells as it is clinically used in the gene therapy protocols for combined immunodeficiency syndroms or hemoglobinopathy [27,28].”
BackgroundMethodUchida, N., Nassehi, T., Drysdale, C. M., Gamer, J., Yapundich, M., Demirci, S., Haro‐Mora, J. J., Leonard, A. K., Hsieh, M. M., & Tisdale, J. F. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.005 · Cited by 49
“gov INTRODUCTION Hematopoietic stem cell (HSC)-targeted gene therapy has been reported to cure various hereditary immunodeficiencies and is under development for hemoglobin disorders, including b-thalassemia and sickle cell disease (SCD).(6,7) In HSC-targeted gene therapy, the defective protein is compensated by deliv…”
BackgroundSynthetic immunology: modulating the human immune system
Geering, B., & Fussenegger, M. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.10.006 · Cited by 50
Ottaviano, G., & Qasim, W. (2025) · Leukemia · doi:10.1038/s41375-025-02585-8 · Cited by 50
“In an early clinical trial adopting SIN-LV for β -globin gene transfer into HSCs for gene therapy for ß-thalassemia, therapeutic bene fi t was achieved enabling transfusion independence [33].”
Hmga2 is a direct target gene of RUNX1 and regulates expansion of myeloid progenitors in mice
Lam, K., Muselman, A., Du, R., Harada, Y., Scholl, A. G., Yan, M., Matsuura, S., Weng, S., Harada, H., & Zhang, D.-E. (2014) · Blood · doi:10.1182/blood-2014-02-554543 · Cited by 46
Di, W., Mellerio, J. E., Bernadis, C., Harper, J. I., Abdul‐Wahab, A., Ghani, S., Chan, L., Martinez-Queipo, M., Hara, H., McNicol, A., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.195 · Cited by 67
Is normal hematopoiesis maintained solely by long-term multipotent stem cells?
Cavazzana, M., Fischer, A., Bushman, F. D., Payen, E., Hacein‐Bey‐Abina, S., & Leboulch, P. (2011) · Blood · doi:10.1182/blood-2010-09-255679 · Cited by 46
Self-citationEfficient gene targeting mediated by a lentiviral vector-associated meganuclease
Izmiryan, A., Basmaciogullari, S., Henry, A., Pâques, F., & Danos, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr524 · Cited by 46
Goodman, M., & Malik, P. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716653729 · Cited by 52
Morgan, R. A., Unti, M. J., Aleshe, B., Brown, D., Osborne, K. S., Koziol, C., Ayoub, P. G., Smith, O. B., O’Brien, R., Tam, C., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.020 · Cited by 49
Wells, D., Guo, S., Shao, W., Bale, M. J., Coffin, J. M., Hughes, S. H., & Wu, X. (2020) · BMC Genomics · doi:10.1186/s12864-020-6647-4 · Cited by 48
Mattar, C. N., Wong, A. M. S., Hoefer, K., Alonso-Ferrero, M. E., Buckley, S. M. K., Howe, S. J., Cooper, J. D., Waddington, S. N., Chan, J. K. Y., & Rahim, A. A. (2015) · The FASEB Journal · doi:10.1096/fj.14-269092 · Cited by 46
Long-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
Bougnères, P., Hacein-Bey-Abina, S., Labik, I., Adamsbaum, C., Castaignède, C., Bellesme, C., & Schmidt, M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.053 · Cited by 45
“Metachromatic leukodystrophy, 11,12 severe combined immunodeficiencies, 13 Wiskott–Aldrich syndrome (WAS), 14–16 b -thalassemia, 17,18 and sickle cell disease 19 were also successfully treated with LV vectors.”
Self-citationHIV-based lentiviral vectors: Origin and sequence differences
Johnson, N. M., Alvarado, A. F., Moffatt, T. N., Edavettal, J. M., Swaminathan, T. A., & Braun, S. E. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.018 · Cited by 49
Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells
Lévy, C., Verhoeyen, E., & Cosset, F. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.003 · Cited by 46
Arens, A., Appelt, J.-U., Bartholomae, C. C., Gabriel, R., Paruzynski, A., Gustafson, D., Cartier, N., Aubourg, P. R., Deichmann, A., Glimm, H., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.219 · Cited by 48
“…X-linked severe combined immunodeficiency (X-SCID) (Gaspar et al. , 2004; Hacein-Bey-Abina et al. , 2002, 2010), chronic granulomatous disease (CGD) (Ott et al. , 2006; Bianchi et al. , 2009), Wiskott-Aldrich syndrome (WAS) (Boztug et al. , 2010), and b - thalassemia (Cavazzana-Calvo et al. , 2010).”
BackgroundSelf-citationConcise Review: Human Cell Engineering: Cellular Reprogramming and Genome Editing
Mali, P., & Cheng, L. (2011) · Stem Cells · doi:10.1002/stem.735 · Cited by 48
“entailed permanent modification of the genome, and hence also significantly raises the risk of insertional mutagenesis [24-28].”
BackgroundGenotoxicity of retroviral hematopoietic stem cell gene therapy
Trobridge, G. D. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.562496 · Cited by 44
“In this study a dominant clone arose that had only one 250-bp cHS4 insulator core element in each LTR, whereas the lentiviral vector used in the study was designed with two copies of this core element to improve insulator activity [17].”
BackgroundMethodInfluentialTolar, J., Adair, J. E., Antoniou, M. N., Bartholomae, C. C., Becker, P. S., Blazar, B. R., Bueren, J. A., Carroll, T., Cavazzana, M., Clapp, D. W., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.78 · Cited by 51
Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy
Biasco, L., Rothe, M., Büning, H., & Schambach, A. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.10.002 · Cited by 49
Ferreira, C. B., Sumner, R. P., Rodriguez-Plata, M. T., Rasaiyaah, J., Milne, R. S. B., Thrasher, A. J., Qasim, W., & Towers, G. J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.021 · Cited by 51
An overview of development in gene therapeutics in China
Wang, D., Wang, K., & Cai, Y. (2020) · Gene Therapy · doi:10.1038/s41434-020-0163-7 · Cited by 45
“Mutations that reduce or abolish the expression of the β-globin chain of hemoglobin cause β-thalassemia [28].”
BackgroundGene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
Domm, J. M., Wootton, S. K., Medin, J. A., & West, M. L. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.07.006 · Cited by 48
Wolff, J. H., & Mikkelsen, J. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00865-4 · Cited by 47
“In one trial, a benign clone carrying a vector integration in the HMGA2 gene was created and found to support therapeutic benefit by disrupting regulation of the transgenic β-globin gene leading to increased production [78].”
BackgroundConcise Review: Managing Genotoxicity in the Therapeutic Modification of Stem Cells
Baum, C., Modlich, U., Göhring, G., & Schlegelberger, B. (2011) · Stem Cells · doi:10.1002/stem.716 · Cited by 44
Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications
Liechtenstein, T., Pérez‐Janices, N., & Escors, D. (2013) · Cancers · doi:10.3390/cancers5030815 · Cited by 52
“In these trials, hematopoietic stem cells were transduced ex vivo and adoptively transferred to patients [116,117].”
BackgroundRecent Advances in β-Thalassemias
Cao, A., Moi, P., & Galanello, R. (2011) · Pediatric Reports · doi:10.4081/pr.2011.e17 · Cited by 53
Retrieval of vector integration sites from cell-free DNA
Cesana, D., Calabria, A., Rudilosso, L., Gallina, P., Benedicenti, F., Spinozzi, G., Schiroli, G., Magnani, A., Acquati, S., Fumagalli, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01389-4 · Cited by 44
Self-citationSuwanmanee, T., Hu, G., Gui, T., Bartholomae, C. C., Kutschera, I., von Kalle, C., Schmidt, M., Monahan, P. E., & Kafri, T. (2014) · Molecular Therapy · doi:10.1038/mt.2013.188 · Cited by 44
Gene Therapy and Gene Editing for β-Thalassemia
Christakopoulos, G. E., Telange, R., Yen, J. S., & Weiss, M. J. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.012 · Cited by 53
Frecha, C. A., Costa, C., Négre, D., Amirache, F., Trono, D., Río, P., Bueren, J. A., Cosset, F., & Verhoeyen, E. (2011) · Blood · doi:10.1182/blood-2011-04-346619 · Cited by 51
Novel genetic therapeutic approaches for modulating the severity of β‑thalassemia (Review)
Amjad, F., Fatima, T., Fayyaz, T., Khan, M. J., & Qadeer, M. I. (2020) · Biomedical Reports · doi:10.3892/br.2020.1355 · Cited by 49
“The first successful gene therapy trial for thalassemia was performed using lentiviral vectors by transducing autologous CD34+ HSCs which encode functional β‐globin and the patient did not require transfusions for the following 2 years (62).”
BackgroundMethodVink, C. A., Counsell, J. R., Perocheau, D. P. B., Karda, R., Buckley, S. M. K., Brugman, M. H., Galla, M., Schambach, A., McKay, T. R., Waddington, S. N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.028 · Cited by 46
Knight, S., Zhang, F., Müller-Kuller, U., Bokhoven, M., Gupta, A., Broughton, T., Sha, S., Antoniou, M. N., Brendel, C., Grez, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00485-12 · Cited by 45
Dissociation of Survival, Proliferation, and State Control in Human Hematopoietic Stem Cells
Knapp, D. J. H. F., Hammond, C. A., Miller, P. H., Rabu, G. M., Beer, P. A., Řičicová, M., Lecault, V., Costa, D. D., VanInsberghe, M. A., Cheung, A. M. S., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.12.003 · Cited by 45
“Years of persisting hematopoiesis in patients given gene-marked autologous cells (Aiuti et al., 2013; Biffi et al., 2013; Cartier et al., 2009; Cavazzana-Calvo et al., 2010) indicate human HSCs maintained ex vivo for a few days can also remain active for many years post-transplant.”
BackgroundIntegrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies
Li, C., Psatha, N., Wang, H., Singh, M., Samal, H. B., Zhang, W., Ehrhardt, A., Izsvák, Z., Papayannopoulou, T., & Lieber, A. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.004 · Cited by 44
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“J Thromb Haemost (2016) 14(6):1121–34.”
Kumar, P., & Chan, W. (2011) · Current Gene Therapy · doi:10.2174/156652311794940782 · Cited by 44
Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yöder, M. C., Leboulch, P., Payen, E., & Srivastava, A. (2016) · Scientific Reports · doi:10.1038/srep35495 · Cited by 44
Self-citationAberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque
Espinoza, D. A., Fan, X., Yang, D., Cordes, S. F., Truitt, L. L., Calvo, K. R., Yabe, I. M., Demirci, S., Hope, K. J., Hong, S. G., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.003 · Cited by 46
“Other clinical trials using LVs containing endogenous or weaker constitutive promoters have reported polyclonal hematopoiesis for years post-transplantation.6,48–51 However, a thalassemia patient developed a marked clonal expansion linked to insertion of an LV containing an internal erythroid-specific promoter, result…”
BackgroundInfluentialFDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis
Garbade, S. F., Zielonka, M., Mechler, K., Kölker, S., Hoffmann, G. F., Staufner, C., Mengel, E., & Ries, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230898 · Cited by 44
“Among those, retroviral and adeno-associated viral (AAV) vectors have been the most widely used in particular for ex vivo T cell engineering or genetically engineered hematopoietic stem cells (HSCs) for the treatment of primarily hematologic or oncologic conditions such as pediatric ALL, β-thalassemia or adenosine dea…”
BackgroundTaher, A. T., Bou‐Fakhredin, R., Kattamis, A., Viprakasit, V., & Cappellini, M. D. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1977116 · Cited by 53
Intravenous injection of a foamy virus vector to correct canine SCID-X1
Burtner, C. R., Beard, B. C., Kennedy, D. R., Wohlfahrt, M. E., Adair, J. E., Trobridge, G. D., Scharenberg, A. M., Torgerson, T. R., Rawlings, D. J., Felsburg, P. J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538926 · Cited by 41
“Trans-activation of HMGA2 by an enhancer element in a lentiviral vector may have contributed to expansion of myeloid cells in a clinical trial for β-thalassemia major.(41) Despite the broad tropism of the foamy virus receptor,(18) only a single integration in the gut of R2203 (Chr21:20,269,587; 40.”
BackgroundCRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications
Ebrahimi, S., Khosravi, M. A., Raz, A., Karimipoor, M., & Parvizi, P. (2023) · ̒Ulūm va funūn-i bastah/bandī · doi:10.61186/ibj.27.5.219 · Cited by 48
Recent trends for novel options in experimental biological therapy of β-thalassemia
Finotti, A., & Gambari, R. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.927434 · Cited by 48
“However, it should be mentioned that the efforts of the groups working in this field have been dedicated to the following major issues: i) highly efficient and stable transduction; ii) targeting of the therapeutic vector to hematopoietic stem cells (HSCs); iii) control of transgene expression (erythroid-specific, diff…”
BackgroundTransplantation for thalassemia major: alternative donors
Locatelli, F., Merli, P., & Strocchio, L. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000280 · Cited by 40
“All rights rese vector [3,4], or the introduction of a lentiviral vector carrying a DNA section encoding the human g-globin gene [5], or the transgenic activation of endogenous g-globin genes [6]) is still confined to the context of experimental protocols, allogeneic hematopoietic stem cell (HSC) transplantation (HSCT…”
BackgroundViral Vector Biosafety in Laboratory Animal Research.
Collins, D. E., Reuter, J. D., Rush, H. G., & Villano, J. (2017) · Europe PMC (PubMed Central) · Cited by 52
Spinozzi, G., Calabria, A., Brasca, S., Beretta, S., Merelli, I., Milanesi, L., & Montini, E. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1937-9 · Cited by 42
Porter, J. B. (2018) · Hematology · doi:10.1182/asheducation-2018.1.361 · Cited by 45
“Autologous CD34(1) cells can be obtained by direct collection from bonemarrow aspiration(16) or from stem cell mobilization.(15,19) Mobilization of CD34(1) cells has been generally achieved using granulocyte colony stimulating factor with or without plerixafor (Table 2).”
BackgroundTherapeutic gene editing in haematological disorders with CRISPR /Cas9
Jensen, T. I., Axelgaard, E., & Bak, R. O. (2019) · British Journal of Haematology · doi:10.1111/bjh.15851 · Cited by 43
“In a study from 2010, an adult patient became transfusion independent after ex vivo autologous gene therapy with a lentiviral vector encoding HBB cDNA (Cavazzana-Calvo et al, 2010).”
BackgroundGene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 42
Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence
Clément, F., Grockowiak, É., Zylbersztejn, F., Fossard, G., Gobert, S., & Maguer‐Satta, V. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.07.03 · Cited by 43
“First hematopoietic cell-based gene therapies were performed to treat primary immunodeficiencies, like X-linked severe combined immunodeficiency (SCID) (39) and other genetic disorders (23).”
BackgroundMethodGenetic therapies for sickle cell disease
Esrick, E. B., & Bauer, D. E. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.014 · Cited by 41
Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice
Sii-Felice, K., Giorgi, M., Leboulch, P., & Payen, E. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.05.004 · Cited by 39
Self-citationDaniel-Moreno, A., Lamsfus‐Calle, A., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0510-8 · Cited by 49
Munis, A. M., Mattiuzzo, G., Bentley, E. M., Collins, M. K., Eyles, J. E., & Takeuchi, Y. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.010 · Cited by 39
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.